Casey D E, Korsgaard S, Gerlach J, Jørgensen A, Simmelsgaard H
Arch Gen Psychiatry. 1981 Feb;38(2):158-60. doi: 10.1001/archpsyc.1981.01780270044005.
The endorphin neuropeptides may have neuroleptic-like effects on dopamine function and may be antischizophrenic. Ten chronic psychotic patients with neuroleptic-induced tardive dyskinesia and parkinsonism received placebo and des-tyrosine-gamma-endorphin (DT gamma E). Drug effects on movement disorders and eye-blinking rates were assessed by blind evaluations of randomly sequenced videotapes made during standardized examinations before and 30, 60, and 120 minutes after each injection and at 24 hours postinjection on days of consecutive treatment. Changes in schizophrenic symptoms were evaluated openly with the schizophrenia subscale of the Comprehensive Psychiatric Rating Scale. There were no significant effects of DT gamma E on any parameter and no side effects. This suggests that DT gamma E, within the tested dose range, does not influence the pathophysiology of neuroleptic-induced dyskinesias or chronic schizophrenia or have neuroleptic properties. However, DT gamma E is well tolerated and should be tested with higher doses during prolonged treatment.
内啡肽神经肽可能对多巴胺功能具有类似抗精神病药物的作用，可能具有抗精神分裂症的特性。十名患有抗精神病药物引起的迟发性运动障碍和帕金森症的慢性精神病患者接受了安慰剂和去酪氨酸 - γ - 内啡肽（DTγE）治疗。通过对标准化检查期间拍摄的随机排序录像带进行盲法评估，来评估药物对运动障碍和眨眼率的影响，这些录像带拍摄于每次注射前、注射后30、60和120分钟以及连续治疗日注射后24小时。使用综合精神病评定量表的精神分裂症分量表对精神分裂症症状的变化进行公开评估。DTγE对任何参数均无显著影响，也无副作用。这表明，在测试剂量范围内，DTγE不会影响抗精神病药物引起的运动障碍或慢性精神分裂症的病理生理学，也不具有抗精神病药物的特性。然而，DTγE耐受性良好，在长期治疗期间应以更高剂量进行测试。
